Our approach to biological drugs (and to high-cost complex drugs* )

To ensure the sound management of our group benefit programs, SSQ Insurance is embarking on an initiative to promote the use of biosimilar drugs (also known as subsequent entry biologics or SEBs).

Effective immediatly, for every new biologic drug expense, we will allow the reimbursement of a biosimilar drug rather than the reference biologic product. Our position reflects the guidelines issued by several provincial public programs in compliance with Health Canada policies.However, all participants being treated with a reference biologic product as a result of a preauthorization will be entitled to reimbursement.

What are biosimilars?

Health Canada has plenty of information available on biologic drugs and biosimilars.

* SSQ Insurance’s approach to high-cost complex drugs is the same as for biologics.